ReviewGastrointestinal tumors2020
Non-Invasive Colorectal Cancer Screening: An Overview.
Review in Gastrointestinal tumors, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 4 syntheses or guidelines pooled it, 103 citations in OpenAlex.
- Pooled it
- Pooled it
- Acceptability of alternative technologies compared with faecal immunochemical test and/or colonoscopy in colorectal cancer screening: A systematic review.Journal of medical screening · 2023Pooled it
- Pooled it
- Comparative Effectiveness of Text + Video vs Text Alone to Prompt Stool-Based Testing for Colorectal Cancer Screening.The Permanente journal · 2025Trial
- Expression Analysis of miRNA Profiles in Colorectal Cancer with a Bioinformatics Approach: An Emphasis on miR-4295, miR-4720-5p, miR-4773, and miR-6831-5p.Diagnostics (Basel, Switzerland) · 2026Article
- The TCN1 Paradox: Unraveling the Dual Role of Transcobalamin I in Colorectal Cancer-From Metabolic Regulation to Oncogenic Signaling.Cancer management and research · 2026Review
- Non-invasive colorectal cancer screening methods: focusing on diagnostic genetic and epigenetic markers.Cancer cell international · 2025Review
- The Role of Epigenetic Biomarkers as Diagnostic, Predictive and Prognostic Factors in Colorectal Cancer.Cancers · 2025Review
- The Future of Tumor Markers: Advancing Early Malignancy Detection Through Omics Technologies, Continuous Monitoring, and Personalized Reference Intervals.Biomolecules · 2025Review
- Colonic Aging and Colorectal Cancer: An Unignorable Interplay and Its Translational Implications.Biology · 2025Review
- Article
- Evaluation of NEUROG1 methylation status in stool specimens in the advanced adenomas and colorectal cancer.PeerJ · 2025Article
- Clinical relevance of plasma-derived exosomal long non-coding RNAs (lncRNAs) CCAT1 and XIST in colorectal cancer patients.Molecular biology research communications · 2025Article
- Innovative approaches in colorectal cancer screening: advances in detection methods and the role of artificial intelligence.Therapeutic advances in gastroenterology · 2025Review
- Clinical Detection and Management of Colorectal Cancer Concerning the Gut Microbiome.Scientifica · 2025Review
- Biomarkers in Colorectal Cancer: Actual and Future Perspectives.International journal of molecular sciences · 2024Review
- Advances in microRNAs as Emerging Biomarkers for Colorectal Cancer Early Detection and Diagnosis.International journal of molecular sciences · 2024Review
- Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments.Cancer metastasis reviews · 2024Review
- Challenges in IBD Research 2024: Precision Medicine.Inflammatory bowel diseases · 2024Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal cancer (CRC) follows a protracted stepwise progression, from benign adenomas to malignant adenocarcinomas. If detected early, 90% of deaths are preventable. However, CRC is asymptomatic in its early-stage and arises sporadically within the population. Therefore, CRC screening is a public health priority. SUMMARY: Faecal immunochemical test (FIT) is gradually replacing guaiac faecal occult blood test and is now the most commonly used screening tool for CRC screening program globally. However, FIT is still limited by the haemoglobin degradation and the intermittent bleeding patterns, so that one in four CRC cases are still diagnosed in a late stage, leading to poor prognosis. A multi-target stool DNA test (Cologuard, a combination of KEY MESSAGE: Maximising the detection accuracy with a cost-effective approach for non-invasive CRC screening is urgently needed to further reduce the incidence of CRC and associated mortality rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.